Most bacterial infections are not caused by free-floating (planktonic) cells, but by biofilms—complex, multicellular communities encased in a self-produced "slime" known as the extracellular polymeric substance (EPS) matrix. This matrix acts as a physical and chemical shield, rendering bacteria up to 1,000 times more resistant to antibiotics than their planktonic counterparts.
Recent research has shifted from trying to kill individual bacteria to dismantling the structural and signaling frameworks that hold these "bacterial fortresses" together. By targeting the matrix and the molecular signals that maintain it, researchers are finding ways to "disarm" bacteria, making them vulnerable to the immune system and conventional treatments.
Dismantling the Signaling Foundation
Biofilms are not static; they are maintained by a constant flow of molecular signals. One of the most critical is the "stringent response," a survival mechanism mediated by the signaling molecule ppGpp. When bacteria are stressed, ppGpp levels rise, triggering the formation and maintenance of the biofilm.
Tian Zhang, Robert E. W. Hancock, and colleagues have pioneered the use of synthetic D-enantiomeric peptides, such as DJK-5, to target this pathway. In Treatment of Oral Biofilms by a D-Enantiomeric Peptide, they demonstrate that DJK-5 works by degrading ppGpp. Without this signal, the bacteria cannot coordinate their stress response, causing the biofilm structure to collapse. Because this mechanism targets a fundamental survival pathway rather than a specific bacterial species, it is effective against complex, multispecies communities like those found in dental plaque.
Physical and Enzymatic Matrix Penetration
If the matrix is a wall, new therapies are designed to be either "drill bits" or "dissolving agents." Standard antibiotics often fail because they cannot penetrate the dense mesh of proteins, polysaccharides, and extracellular DNA (eDNA) that make up the EPS.
Engineered Peptides as Matrix Drills
Researchers like Marlon H. Cardoso and Suzana M. Ribeiro have developed "shape-shifting" peptides like Pa-MAP 1.9. As described in A polyalanine peptide derived from polar fish with anti-infectious activities, these molecules are specifically optimized to penetrate the protective matrix. Interestingly, these peptides often show higher potency against bacteria within a biofilm than against free-swimming cells, suggesting they possess a specific affinity for the biofilm's unique physical environment.
Similarly, Osmar Nascimento Silva has characterized Clavanin A, a peptide that excels at disrupting the protective "slime" of biofilms even at concentrations that don't kill planktonic bacteria. This indicates a mechanism focused on structural disruption rather than general toxicity.
Bacteriophages as Enzymatic Softeners
Bacteriophages (viruses that infect bacteria) offer a different approach: enzymatic degradation. Phages like ΦK2046 produce enzymes during their lytic cycle that physically weaken the EPS. Panjie Hu and colleagues show in Isolation and identification of Klebsiella pneumoniae phage ΦK2046 that this "softening" increases the porosity of the biofilm, allowing secondary agents like chlorhexidine to reach deeper layers of the bacterial community.
Triggering the Molecular Eject Button
Biofilms have a natural life cycle that includes a "dispersion" phase, where bacteria leave the matrix to colonize new sites. Researchers are now attempting to hijack the signals that trigger this phase to force biofilms to dissolve.
A key regulator of this process is c-di-GMP, a secondary messenger that acts as a "glue" signal; high levels promote biofilm formation, while low levels trigger dispersion. In Pseudomonas aeruginosa biofilm dispersion by the mouse antimicrobial peptide CRAMP, Yang Zhang and Rendong Fang describe how the peptide CRAMP lowers intracellular c-di-GMP. This metabolic shift reduces the production of "glue" (EPS) while upregulating biological surfactants that act as detergents, actively pushing bacteria out of the matrix and into a vulnerable, planktonic state.
Repurposing and Synergy
The realization that the matrix is the primary barrier has led to the discovery of anti-biofilm properties in unexpected places.
- Antifibrinolytics: Jiahao Wang found that Tranexamic acid (TXA), typically used to stop surgical bleeding, prevents bacteria from establishing a foothold on medical implants. It does this by specifically reducing the protein and polysaccharide components of the EPS, preventing the "glue" from setting (Tranexamic acid protects against implant-associated infection by reducing biofilm formation).
- Traditional Medicine: Jun Liu demonstrated that Yunnan Baiyao suppresses the agr quorum-sensing system in S. aureus, downregulating the genes responsible for releasing eDNA. Without eDNA to act as a structural scaffold, the resulting biofilm is physically weaker and easily cleared by the host immune system (Yunnan Baiyao reduces hospital-acquired pressure ulcers).
By focusing on the "house" the bacteria live in rather than just the bacteria themselves, these diverse strategies—ranging from synthetic peptides to repurposed surgical drugs—provide a blueprint for overcoming the resilience of chronic, biofilm-mediated infections.